Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS.

TitleFrontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS.
Publication TypeJournal Article
Year of Publication2017
AuthorsVeenstra, M, Williams, DW, Calderon, TM, Anastos, K, Morgello, S, Berman, JW
JournalJ Leukoc Biol
Volume102
Issue5
Pagination1173-1185
Date Published2017 Nov
ISSN1938-3673
KeywordsAdult, Antigens, CD14, Antiretroviral Therapy, Highly Active, Astrocytes, Blood-Brain Barrier, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Cognitive Dysfunction, Endothelial Cells, Female, Gene Expression, GPI-Linked Proteins, HIV Infections, HIV-1, Humans, Immunologic Factors, Male, Middle Aged, Models, Biological, Monocytes, Primary Cell Culture, Receptors, CXCR, Receptors, IgG, Transendothelial and Transepithelial Migration, Viral Load
Abstract

CD14(+)CD16(+) monocytes transmigrate into the CNS of HIV-positive people in response to chemokines elevated in the brains of infected individuals, including CXCL12. Entry of these cells leads to viral reservoirs, neuroinflammation, and neuronal damage. These may eventually lead to HIV-associated neurocognitive disorders. Although antiretroviral therapy (ART) has significantly improved the lives of HIV-infected people, the prevalence of cognitive deficits remains unchanged despite ART, still affecting >50% of infected individuals. There are no therapies to reduce these deficits or to prevent CNS entry of CD14(+)CD16(+) monocytes. The goal of this study was to determine whether CXCR7, a receptor for CXCL12, is expressed on CD14(+)CD16(+) monocytes and whether a small molecule CXCR7 antagonist (CCX771) can prevent CD14(+)CD16(+) monocyte transmigration into the CNS. We showed for the first time that CXCR7 is on CD14(+)CD16(+) monocytes and that it may be a therapeutic target to reduce their entry into the brain. We demonstrated that CD14(+)CD16(+) monocytes and not the more abundant CD14(+)CD16(-) monocytes or T cells transmigrate to low homeostatic levels of CXCL12. This may be a result of increased CXCR7 on CD14(+)CD16(+) monocytes. We showed that CCX771 reduced transmigration of CD14(+)CD16(+) monocytes but not of CD14(+)CD16(-) monocytes from uninfected and HIV-infected individuals and that it reduced CXCL12-mediated chemotaxis of CD14(+)CD16(+) monocytes. We propose that CXCR7 is a therapeutic target on CD14(+)CD16(+) monocytes to limit their CNS entry, thereby reducing neuroinflammation, neuronal damage, and HIV-associated neurocognitive disorders. Our data also suggest that CCX771 may reduce CD14(+)CD16(+) monocyte-mediated inflammation in other disorders.

DOI10.1189/jlb.3HI0517-167R
Alternate JournalJ. Leukoc. Biol.
PubMed ID28754798
PubMed Central IDPMC5636044